Editorial overview: Dealing with death: HMGB1 as a novel target for cancer therapy

Current Opinion in Investigational Drugs

Volumn 4, Issue 12, 2003, Pages 1405-1409

  Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIBODY; ANTINEOPLASTIC AGENT; DNA; HIGH MOBILITY GROUP B1 PROTEIN; HORMONE RECEPTOR; INTEGRIN; LIGAND; TUMOR NECROSIS FACTOR; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; RAGE PROTEIN, HUMAN; TUMOR ANTIGEN;

APOPTOSIS; ARTHRITIS; BIOLOGY; CANCER; CANCER CLASSIFICATION; CANCER THERAPY; CELL ADHESION; CELL DEATH; CHROMATIN; CHRONIC DISEASE; CHRONIC INFLAMMATION; DISEASE MODEL; DRUG TARGETING; EDITORIAL; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; ILLNESS BEHAVIOR; IMMUNE DEFICIENCY; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; NECROSIS; NONHUMAN; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SEPSIS; SIGNAL TRANSDUCTION; TISSUE INJURY; TUMOR GROWTH; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL DEATH; DRUG DELIVERY SYSTEMS; HMGB1 PROTEIN; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; RECEPTORS, IMMUNOLOGIC;

EID: 1642434067     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (60)

1. Taylor SL, Renshaw BR, Garka KE, Smith DE, Sims JE: Genomic organization of the interleukin-1 locus. Genomics (2002) 79(5):726-733.
2. Nicklin MJ, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Kornman K: A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics (2002) 79(5):718-725.
3. Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto A: Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol (2003) 170(1):107-113.
4. Wang H, Czura CJ, Tacey KJ: HMGB1. In: The Cytokine Handbook, 4th Edition. Thomson AW, Lotze MT (Eds), Academic Press, London, UK (2003):913-923.
5. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ: HMGB1 as a DNA-binding cytokine. J Leukocyte Biol (2002) 72(6):1084-1091.
6. Bustin M: At the crossroads of necrosis and apoptosis: Signaling to multiple cellular targets by HMGB1. Sci STKE (2002) 2002(151):PE39.
7. Degryse B, De Virgilio M: The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett (2003) 553(1-2):11-17.
8. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J (2003) 22(20):5551-5560.
9. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, Schmidt AM: RAGE is a multiligand receptor of the immunoglobulin superfamily: Implications for homeostasis and chronic disease. Cell Mol Life Sci (2002) 59(7):1117-1128.
10. Stern DM, Yan SD, Yan SF, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev (2002) 1(1):1-15.
11. Schmidt AM, Stern DM: Receptor for age (RAGE) is a gene within the major histocompatibility class III region: Implications for host response mechanisms in homeostasis and chronic disease. Front Biosci (2001) 6:D1151-D1160.
12. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest (2001) 108(7):949-955.
13. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A: The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep (2002) 3(10):995-1001.
14. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 418(6894):191-195.
15. Colomar A, Marty V, Medina C, Combe C, Parnet P, Amedee T: Maturation and release of interleukin-1β by lipopolysaccharide-primed mouse schwann cells require the stimulation of P2X7 receptors. J Biol Chem (2003) 278(33):30732-30740.
16. Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB, Robertson B, Posmantur R: P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem (2003) 278(15):13309-13317.
17. Aldrich MB, Chen W, Blackburn MR, Martinez-Valdez H, Datta SK, Kellems RE: Impaired germinal center maturation in adenosine deaminase deficiency. J Immunol (2003) 171(10):5562-5570.
18. O'Connor KA, Hansen MK, Rachal Pugh C, Deak MM, Biedenkapp JC, Milligan ED, Johnson JD, Wang H, Maier SF, Tracey KJ, Watkins LR: Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: Central nervous system effects. Cytokine (2003) 24(6):254-265.
19. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 285(5425):248-251.
20. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF: Inflammatory promoting activity of HMGB1 on human microvascular endothelial cells. Blood (2003) 101(7):2652-2660.
21. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE: High mobility group 1 B-box mediates activation of human endothelium. J Intern Med (2003) 254(4):375-385.
22. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, Ulloa L, Yang H, Yan XJ, Furie R, Chiorazzi N et al.: High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis. Arthritis Rheum (2002) 46(10):2598-2603.
23. Pullerits R, Jonsson IM, Verdrengh M, Bokarewa M, Andersson U, Erlandsson-Harris H, Tarkowski A: High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum (2003) 48(6):1693-1700.
24. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T et al.: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum (2003) 48(4):971-981.
25. DeMarco RA, Fink M, Lotze MT: HMGB1 promotes macrophage dependent production of interferon γ by human NK cells: Cellular synergy. J Immunother (2003) 26:S2.
26. Mattson MP, Kroemer G: Mitochondria in cell death: Novel targets for neuroprotection and cardioprotection. Trends Mol Med (2003) 9(5):196-205.
27. Nieminen AL: Apoptosis and necrosis in health and disease: Role of mitochondria. Int Rev Cytol (2003) 224:29-55.
28. Naghavi MH, Nowak P, Andersson J, Sonnerborg A, Yang H, Tracey KJ, Vahlne A: Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner. Virology (2003) 314(1):179-189.
29. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med (2003) 198(10):1507-1515.
30. Banerjee S, Kundu TK: The acidic C-terminal domain and A-box of HMGB-1 regulates p53-mediated transcription. Nucleic Acids Res (2003) 31(12):3236-3247.
31. Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M, Kohno K, Takenaka K, Sugimachi K, Kuwano M: Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res (1996) 56(23):5330-5333.
32. Hirata K, Takada M, Suzuki Y, Kuroda Y: Expression of receptor for advanced glycation end products (RAGE) in human biliary cancer cells. Hepatogastroenterology (2003) 50(53):1205-1207.
33. Kuniyasu H, Chihara Y, Takahashi T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep (2003) 10(2):445-448.
34. Edwards JG, Swinson DE, Jones JL, Muller S, Waller DA, O'Byrne KJ: Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest (2003) 124(5):1916-1923.
35. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, Zornig M: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J (2003) 17(10):1295-1297.
36. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, Paik YK, Kim HO, Kim H: Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res (2003) 63(9):2188-2193.
37. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R: Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep (2003) 10(6):1863-1868.
38. Swinson DE, Jones JL, Richardson D, Cox G, Edwards JG, O'Byrne KJ: Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: Correlation with biological variables. Lung Cancer (2002) 37(3):235-240.
39. Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor SG IV: Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: A 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol (1993) 11(10):1929-1935.
40. Kato T, Kameoka S, Kimura T, Tanaka S, Nishikawa T, Kobayashi M: p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. Anticancer Res (2002) 22(2B):1105-1112.
41. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, Janicke F, Graeff H: Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clin Cancer Res (1995) 1(7):741-746.
42. Prasad ML, Patel S, Hoshaw-Woodard S, Escrig M, Shah JP, Huvos AG, Busam KJ: Prognostic factors for malignant melanoma of the squamous mucosa of the head and neck. Am J Surg Pathol (2002) 26(7):883-892.
43. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol (2001) 19(16):3622-3634.
44. Gustafson P, Akerman M, Alvegard TA, Coindre JM, Fletcher CD, Rydholm A, Willen H: Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis-the SIN-system. Eur J Cancer (2003) 39(11):1568-1576.
45. Miyajima K, Oda Y, Oshiro Y, Tamiya S, Kinukawa N, Masuda K, Tsuneyoshi M: Clinicopathological prognostic factors in soft tissue leiomyosarcoma: A multivariate analysis. Histopathology (2002) 40(4):353-359.
46. Hunter GJ, Willson SA, Chapman M: Necrotic carcinoma of the colon. Clin Radiol (1983) 34(3):297-299.
47. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 27(5):612-624.
48. Taguchi A, Blood DC, Del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA et al.: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 405(6784):354-360.
49. Landis RC, Yagnik DR, Florey O, Philippidis P, Emons V, Mason JC, Haskard DO: Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum (2002) 46(11):3026-3033.
50. Olexa P, Olexova M, Gonsorcik J, Tkac I, Kisel'ova J, Olejnikova M: Uric acid - A marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr (2002) 114(5-6):211-215.
51. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole-Wilson PA, Coats AJ: Uric acid in chronic heart failure: A marker of chronic inflammation. Eur Heart J (1998) 19(12):1814-1822.
52. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature (2003) 425(6957):516-521.
53. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, Susarla S, Czura C, Mitchell RA, Chen G, Sama AE et al.: IFN-γ induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol (2003) 170(7):3890-3897.
54. Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE: A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res (2003) 63(1):100-106.
55. Czura CJ, Yang H, Tracey KJ: High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor. J Infect Dis (2003) 187(Suppl 2):S391-S396.
56. Agresti A, Lupo R, Bianchi ME, Muller S: HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun (2003) 302(2):421-426.
57. Hirt UA, Leist M: Rapid, noninflammatory and PS-dependent phagocytic clearance of necrotic cells. Cell Death Differentiation (2003) 10(10):1156-1164.
58. Essmann F, Bantel H, Totzke G, Engels IH, Sinha B, Schulze-Osthoff K, Janicke RU: Staphylococcus aureus α-toxin-induced cell death: Predominant necrosis despite apoptotic caspase activation. Cell Death Differentiation (2003) 10(11):1260-1272.
59. Yamada S, Inoue K, Yakabe K, Imaizumi H, Maruyama I: High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem (2003) 49(9):1535-1537.
60. Lotze MT, DeMarco RA, Vakkila J: Inhibition of the growth promoting death signals in tumor biology: A hypothesis. J Immunother (2003) 26:S27.